Hemab Therapeutics Holdings, Inc. COAG
—
34.74
(0.98)
(2.74%)
as of 25 Sep
- Market cap
- $1.7B
- P/E
- 0.0×
Follow COAG
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | (31.79%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (16.46%) | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (2.42) | |
Free Cash Flow |
— | — | — | (72.74) | |
Capital Expenditures |
— | — | — | (0.15) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 0.00% | (7.96%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | — | — | 0.98 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.50 | |
Capex/Depreciation |
— | — | — | (0.50) | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | (2.41) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates